3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
56
Fallopian Tube Neoplasms
25
Breast Neoplasms
18
Neoplasms
14
Carcinoma, Ovarian Epithelial
14
Multiple Myeloma
9
Neoplasm Metastasis
7
Triple Negative Breast Neoplasms
3
Recurrence
3
Peritoneal Neoplasms
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Solid Tumors
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Ovarian Cancer Recurrent
2
Liver Neoplasms
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Disease Progression
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
liposomal doxorubicin
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled